Menu

AstraZeneca

Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis

, ,

Study Met All Primary Endpoints Against Stelara® (ustekinumab) and Placebo Three Pivotal Studies Form the Basis for Global Regulatory Filings, Planned In 2015 THOUSAND OAKS, Calif. and LONDON, Nov. 25, 2014 /PRNewswire/ — Amgen (NASDAQ: AMGN) and AstraZeneca (NYSE: AZN) today announced that AMAGINE-2TM, a pivotal, multi-arm Phase 3 trial evaluating two doses of brodalumab […]

MedImmune and Immunocore enter immunotherapy agreement to develop novel cancer therapies

, , ,

January 8, 2014 – AstraZeneca today announced that MedImmune, its global biologics research and development arm, has entered into an oncology research collaboration and licensing agreement with Immunocore Limited, a privately-held, UK-based biotechnology company. Both companies will research and develop novel cancer therapies using Immunocore’s Immune Mobilising Monoclonal T-Cell Receptor Against Cancer (ImmTAC) technology. This platform […]

AstraZeneca and Shionogi settle arbitration and extend licence agreement for CRESTOR®

, , ,

December 26, 2013 – AstraZeneca and Shionogi & Co. Ltd. today announced the full resolution of arbitration proceedings related to the treatment of certain excise taxes and other specific items in the calculation of royalties on CRESTOR® sales. In addition, AstraZeneca and Shionogi & Co. Ltd. announced the extension of the global licence agreement for CRESTOR® […]

AstraZeneca to acquire Bristol-Myers Squibb share of global diabetes alliance assets

, , , ,

Global agreement strengthens AstraZeneca’s commitment to diabetes, a key growth platform in a core strategic area for the company December 19 , 2013 – AstraZeneca today announced an agreement under which AstraZeneca will acquire the entirety of Bristol-Myers Squibb’s interests in the companies’ diabetes alliance for an initial consideration of $2.7 billion on completion and up […]